Novartis starts 2018 on ‘solid ground’Wednesday’s Les Echos (website) published an article on Novartis, judging the company was starting 2018 “on solid ground”.
Sanofi engages in sale of generics business, enters haemophilia marketSanofi was the main subject of interest this week in the French media, with the announcement of its acquisition of haemophilia specialist Bioverativ (Tuesday’s Les Echos, p38; Wednesday’s Le Monde, p1), and the kickstart of the sale process of its generics business (Monday’s Les Echos, brief p18).
Celgene acquires Juno for $9 billionTuesday’s Le Figaro (website) and Les Echos (p18) reported on Celgene’s takeover offer for Juno Therapeutics (APMHE 56531).
Dominique Carouge joins Sanofi’s executive committeeOn Wednesday, Les Echos (brief p35) announced that Dominique Carouge will join Sanofi’s executive committee, as vice-president in charge of business transformation.
New CSO for Innate PharmaOn Wednesday, Les Echos (p34) published a feature on Eric Vivier, who was recently appointed chief scientific officer and vice-president of French biotech Innate Pharma.
Alzprotect biotech raises 14 million eurosFrench biotech Alzprotect has raised 14 million euros from private investors, Les Echos announced on Monday (p28).
Allergan boosts dermal fillers manufacturing at French plantThursday’s Les Echos (brief p25) and Le Figaro (website) reported that Allergan is to invest 48 million euros in its Prigy manufacturing site, in order to increase production capacities for dermal fillers based on hyaluronic acid.
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.